Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
08:00Gianluca Milanese, Parma / IT
3
Evaluation of differential response in patients with metastatic lung cancer treated with immune checkpoint inhibitors: a pilot study
08:00Andreu Antolín Redondo, Barcelona / ES
4
Comparison of performance by whole-body MRI, PET/MRI and PET/CT and conventional staging methods for TNM and VALSG staging of small cell carcinoma patients
08:00Yoshiharu Ohno, Toyoake / JP
5
To differentiate pulmonary sclerosing pneumocytoma from atypical lung cancer based-on contrast-enhanced CT: a radiomic analysis
08:00Lei Wang, Nanchang / CN
6
Differentiation of benign lung nodules and lung metastases: a radiomics approach in a large cancer patient cohort
08:00Simon Lennartz, Köln / DE
PEP Subscription Required
This course is only accessible for ESR Premium Education Package subscribers.